Search for a trial

A novel causative gene of congenital central hypothyroidism.

1) To perform gene mutation analysis in family members of patients carrying a proven mutation in the candidate gene.2) To determine the clinical, biochemical and radiological characteristics of carriers of a mutation in the candidate gene.3) To…

Influence of exogenous growth hormone administration on circulating levels of Klotho in paediatric patients with isolated growth hormone deficiency.

To assess the impact of treatment with rhGH on circulating Klotho levels in paediatric patients with IGHD.

Unraveling genetic causes of congenital multiple pituitary hormone deficiencies

To find new genes causing congenital MPHD associated with the characteristic MRI abnormalities of ectopic posterior pituitary gland and absent/thin pituitary stalk.

Assessment of Bone Material Strength by Microindentation in vivo in Patients with Acromegaly

To assess Bone Material Strength (BMS) in patients with acromegaly with fractures and without fractures.

Short-term Efficacy of Stellate Ganglion Block in Men to reduce Hot Flushes related to Androgen Deprivation Therapy

To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus sham procedure

A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing*s disease

The purpose of this study, is to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing*s disease as measured by the proportion of patients achieving normal UFC at the end of the study…

A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing*s disease

To assess the efficacy and safety of LCI699 in CD patients

Congenital central hypothyroidism plusminus ACTH or growth hormone deficiency: etiology and outcome

In this predominantly observational study all patients diagnosed with CH-C in the Netherlands between 1-1-1995 and 1-1-2015 will be traced and the following research questions will be addressed:1) What is the mortality rate associated with early…

Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of lanreotide PRF in subjects with acromegaly previously treated and controlled with either ocreotide LAR or lanreotide Autogel.

Primary:*To identify the maximum tolerated dose (MTD) and to investigate the pharmacokinetics (PK) of a single dose of lanreotide PRF in subjects with acromegalySecondary:*To investigate the safety and tolerability of a single dose of lanreotide PRF…